TEVATeva Pharmaceutical Industries Limited

$36B

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.7B-17.3% YoY

Gross Profit

$2.1B43.8% margin

Operating Income

-$14M-0.3% margin

Net Income

-$176M-3.7% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-7.2%

Cash Flow

Operating Cash Flow

$162M

Free Cash Flow

$26M

Stock-Based Comp.

$47M

Balance Sheet

Total Assets

$67.0B

Total Liabilities

$47.7B

Stockholders' Equity

$17.9B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.7B	$5.7B	-17.3%
Gross Profit	$2.1B	$2.8B	-26.9%
Operating Income	-$14M	-$5.7B	+99.8%
Net Income	-$176M	-$6.0B	+97.1%

Revenue Segments

International Markets

$789M71%

Other Activities

$321M29%

Geographic Segments

North America

$1.9B59%

Europe

$1.3B41%

TEVA Q2 2018 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena